Richard Cook, MD
Family Medicine · Uniontown, PANPI 1568527653
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $563 of the $682 with a category attached, or 82.6%. 7 manufacturers reported payments, led by Pfizer at 46.0% of the total.
Across 39 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$314
- AstraZeneca$119
- Novo Nordisk$115
- AbbVie$89
- Eisai Inc.$19
- Johnson & Johnson$15
- plus $11 from 1 others
Across 94 payments — averaging $23,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Eli Lilly$530K
- AstraZeneca$91K
What the payments were for
- Travel & lodging$11917%
- Food & beverage$56383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $314 |
| AstraZeneca | 2 | $119 |
| Novo Nordisk | 6 | $115 |
| AbbVie | 5 | $89 |
| Eisai Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$682 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $306,710 |
| JardianceEmpagliflozin | 153 | $185,514 |
| EliquisApixaban | 142 | $153,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $64,132 |
| TrulicityDulaglutide | 47 | $54,229 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $50,310 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $36,711 |
| JanuviaSitagliptin Phosphate | 39 | $34,564 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $28,603 |
| XareltoRivaroxaban | 40 | $25,122 |
| EntrestoSacubitril/Valsartan | 25 | $21,441 |
| RybelsusSemaglutide | 15 | $20,658 |
| MounjaroTirzepatide | 14 | $15,263 |
| FarxigaDapagliflozin Propanediol | 19 | $14,605 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $13,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $115 | $327,368261 claims |
| PfizerEliquis | $314 | $153,875142 claims |
| Johnson & JohnsonXarelto | $15 | $25,12240 claims |
| AstraZenecaFarxiga | $119 | $14,60519 claims |
| AbbVieSynthroid | $89 | $2,20457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Uniontown
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.